Introduction {#Sec1}
============

Acute promyelocytic leukemia (APL) is a rare subtype of acute myeloid leukemia (AML) that accounts for \< 10% of all AMLs, with an estimated incidence of 0.1/100,000 in Western countries \[[@CR1]\]. APL is characterized by a distinctive blast morphology, the presence of coagulopathy at diagnosis, and a specific balanced reciprocal translocation *t*(15;17), which fuses the promyelocyte (*PML*) gene on chromosome 15 to the retinoic acid receptor alpha (*RARα*) gene on chromosome 17. APL is a medical emergency requiring prompt diagnosis and management. Indeed, the disease frequently presents in combination with a consumptive life-threatening coagulopathy. The treatment of APL has undergone a revolution over the past two decades due to the advent of therapy based on all-*trans* retinoic acid (ATRA) and arsenic trioxide (ATO), which are known to target *RARα* and *PML*, the two distinct moieties of the disease-specific oncoprotein PML/RARα \[[@CR2]\]. The results of large trials of various combinations of ATRA, ATO, and chemotherapy in a number of countries have transformed the prognosis for this type of leukemia, with long-term remission rates now exceeding 80% \[[@CR3]--[@CR6]\]. Recently, large randomized trials comparing the standard ATRA plus chemotherapy approach with an ATRA-ATO chemotherapy-free combination have shown a benefit of the chemotherapy-free approach, leading to new treatment guidelines for APL patients \[[@CR7]--[@CR9]\]. Thus, the story of APL can serve as a model for the development of targeted therapies and curative approaches for malignant diseases.

In this brief review, we examine the major advances made in the history of APL therapy, from the initial description of the disease to its present status (Fig. [1](#Fig1){ref-type="fig"}). Targeted more specifically at the young hematologist and the general educated reader, this review provides accounts of scientific and medical discoveries and practices in this domain. It utilizes chronology as an organizing framework while stressing the importance of themes.Fig. 1Highlights in the history of APL treatment

The article is based on previously conducted studies and does not contain any studies with human participants or animals performed by the author.

First Descriptions and Treatments {#Sec2}
=================================

APL was first described in 1957 by the Norwegian hematologist Leif Hillestad, who detailed three cases of a special type of AML characterized by "a very rapid fatal course of only a few weeks' duration, a white blood cell picture dominated by promyelocytes, a severe bleeding tendency due to fibrinolysis and thrombocytopenia, a normal erythrocyte sedimentation rate, probably caused by the reduced fibrinogen concentration in the plasma." He suggested denoting this type of AML *acute promyelocytic leukemia*, and concluded that "it seems to be the most malignant form of acute leukemia" \[[@CR10]\] (Fig. [2](#Fig2){ref-type="fig"}). One of those three patients was previously described by Stormorken \[[@CR11]\], and in his paper Hillestad mentioned three other previously reported \[[@CR12]--[@CR14]\] patients with identical symptoms to his cases, who may therefore also have been APL patients.Fig. 2APL was first described in 1957 by Leif Hillestad, who published three cases of a special type of AML in*Acta Medica Scandinavica*

More detailed features of APL were described by Bernard in 1959, who reported a series of 20 patients \[[@CR15]\]. Severe hemorrhagic diathesis was recognized as the most prominent clinical feature of APL, as it accounted for most of the fatal events at presentation and during initial cytotoxic treatment. This has been ascribed to disseminated intravascular coagulation (DIC) or hyperfibrinolysis triggered by APL blasts \[[@CR16]\].

The predominant malignant cells were described as abnormal promyelocytes with an immature nucleus and a cytoplasm filled with azurophilic granules. In 1976, the French-American-British (FAB) Nomenclature Committee categorized them as M3 cells (hypergranular promyelocytic leukemia), with the following characteristics: "The great majority of cells are abnormal promyelocytes, with a characteristic pattern of heavy granulation. The nucleus varies greatly in size and shape and is often reniform or bilobed. The cytoplasm of most of the cells is completely occupied by closely packed or even coalescent large granules. In some cells the cytoplasm is filled with fine dust-like granules. Characteristic cells containing bundles of Auer rods ('faggots') randomly distributed in the cytoplasm are almost invariably present in the bone marrow and sometimes in the peripheral blood. A variable but often high proportion of the hypergranular promyelocytes and the faggot cells are disrupted" \[[@CR17]\]. Four years later, a microgranular variant (M3v) form of the disease with usually bilobed cell nuclei, no granules visible on light microscopy, and a positive myeloperoxidase reaction was identified in approximately 20% of the cases and recognized in an updated FAB classification \[[@CR18]\] (Fig. [3](#Fig3){ref-type="fig"}). A very rare third variant form---basophilic microgranular APL---was described in 1982 \[[@CR19]\], and is characterized by cells with a high nucleus/cytoplasm ratio and strongly basophilic cytoplasm with sparse or no granules.Fig. 3Morphologic variants of APL

Early studies with induction including 6-mercaptopurine (6-MP) alone or in combination with steroids, methyl-glyoxalguanyl hydrazine, and/or methotrexate led to poor results with complete remission (CR) rates ranging from 5 to 14% and survival periods of 3--16 weeks (median 3.5 weeks) among all patients and 4 months to more than 6 years among responders. Furthermore, the best way of managing the bleeding diathesis remained unclear \[[@CR15], [@CR20]--[@CR22]\].

The first important success in APL therapy was reported by Bernard et al. \[[@CR23]\], who showed that the disease was particularly sensitive to treatment with anthracyclines, and obtained high rates of CR (19 of 34 APL patients; 55%) with daunorubicin given as monotherapy. A significant proportion of these patients (approximately 30%) experienced long-term remission. Consequently, anthracycline-based chemotherapy became one of the mainstays of APL treatment.

By the end of this period, APL had been morphologically and clinically characterized but kept a dismal prognosis, especially because of fatal coagulation disorders.

Chemotherapy During the Pre-All-*Trans* Retinoic Acid Era {#Sec3}
=========================================================

Between 1980 and 1988, studies focused on the management of APL treatment and on the identification of prognostic factors. The beneficial effect of anthracycline treatment was confirmed \[[@CR24]--[@CR27]\]. Following the demonstration that APL cells are relatively sensitive to daunorubicin \[[@CR23]\] and that AML cells respond to cytarabine \[[@CR28]\], chemotherapy composed of an anthracycline and cytosine arabinoside became the frontline treatment for APL. With this combination, CR rates reached 80% in newly diagnosed patients \[[@CR29]\], but were not very different from those seen for treatment with anthracycline alone \[[@CR25], [@CR29]--[@CR31]\]. However, the frequently observed aggravation of hemorrhagic diathesis by chemotherapy during the first days of treatment, which leads to a high early death rate, necessitated intensive management based on platelet and fibrinogen support \[[@CR31]--[@CR33]\]. There were contentious discussions regarding the origins of the fibrinogenopenia (either secondary or primary fibrinolysis) as well as the optimal treatment for it: low-dose heparin, antifibrinolytic agents, or platelet transfusions alone. The most consistent coagulation abnormalities were prolongation of the prothrombin and thrombin times, elevation of fibrinogen degradation products, and decreased levels of factor V and fibrinogen. Gralnick and Abrell \[[@CR34]\] compared the procoagulant (tissue factor) and fibrinolytic activities of malignant promyelocytes to those of other AML cells, and found markedly increased tissue factor activity in promyelocytes. Normal levels of protein C and antithrombin III combined with acquired reduced alpha-2 antiplasmin levels implied a fibrinolytic process rather than DIC \[[@CR35]\]. Regarding therapy, low-dose heparin (50 U/kg) given every 4--6 h or in continuous perfusion (100--200 U/kg/day) was shown to result in clinical and laboratory improvement \[[@CR36]\]. Platelet transfusions were also shown to be useful for controlling the hemorrhagic diathesis, with the aim being to keep the platelet count close to 50 × 10^9^/L. Fresh frozen plasma, plasma fractions, or fibrinogen did not prove useful for preventing hemorrhage \[[@CR36]\].

Despite a significant improvement in outcome, the median duration of remission ranged from 11 to 24 months with a 5-year disease-free survival (DFS) of only 35--45% in patients treated by chemotherapy alone (Table [1](#Tab1){ref-type="table"}) \[[@CR25], [@CR29], [@CR37]--[@CR43]\]. The early mortality rate was approximately 15% and the resistant rate was 10%. Resistance could be reduced by applying a more aggressive anthracycline treatment \[[@CR25], [@CR29], [@CR44]\]. To increase survival, maintenance therapy with 6-MP and methotrexate was suggested \[[@CR25], [@CR29], [@CR38]\].Table 1Data on large published series of APL patients treated with combinations of cytotoxic agents during the pre-ATRA eraReferencePeriodNo. of patientsInduction regimenCR (%)Median DFSMarty et al. \[[@CR25]\]1972--198260DNR7017 months18DNR + AraC7248 months (maintenance)Cordonnier et al. \[[@CR37]\]1972--198257DNR + AraC ± other5311 monthsKantarjian et al. \[[@CR38]\]1973--198460Amsa or DNR + AraC5315 monthsAdr + AraC ± otherNA (maintenance)Goldberg et al. \[[@CR39]\]1974--198534DNR or Adr + AraC7424 monthsHoyle et al. \[[@CR40]\]1976--1986115DNR + AraC + TG6013 monthsSanz et al. \[[@CR41]\]1976--198634DNR6824 monthsCunningham et al. \[[@CR42]\]1974--198353DNR or Amsa + AraC + TG7215 monthsRodeghiero et al. \[[@CR31]\]1984--1987131DNR67NA137DNR or Adr + AraC ± other58NAThomas et al. \[[@CR43]\]1974--198967DNR + AraC ± other6416 monthsFenaux et al. \[[@CR29]\]1974--198870DNR8017 monthsDNR + AraCNA (maintenance)Amsa or RBZ + AraC*Adr* adriamycin, *Amsa* amsacrine, *AraC* cytarabine, *CR* complete remission, *DFS* disease-free survival, *DNR* daunorubicin, *NA* not available, *RBZ* rubidazone, *TG* thioguanine

Several prognostic factors were rapidly identified, such as severe fibrinopenia and a high white blood cell (WBC) count at diagnosis \[[@CR23]\]. Other prognostic factors included age, fever, high blast count, serum creatinine, hyperuricemia, lactate dehydrogenase level, and albumin level \[[@CR38], [@CR40], [@CR43]\]. Factors predictive of hemorrhagic deaths were age, high blast cell count, thrombocytopenia, prothrombin time, fibrinogen level, and anemia \[[@CR31], [@CR38], [@CR40], [@CR43]\].

At 2 years, the relapse rate was approximately 35%. A variety of reinduction methods were attempted in the pre-ATRA era. A second CR was reported in 53% of cases \[[@CR38]\]. Allogeneic and autologous hematopoietic stem cell transplantation (HSCT) resulted in a longer duration of second CR \[[@CR38], [@CR42], [@CR45]\].

At the biological level, a major breakthrough during this period was the confirmation that APL is a distinct entity based on the presence of an abnormal cytogenetic feature. First considered by Golomb et al. to be a partial deletion of chromosome 17 \[[@CR46]\], the abnormality was identified a year later as a balanced reciprocal translocation between the long arms of chromosomes 15 and 17:*t*(15;17) (q21;q22) \[[@CR47]\], which was consistently associated with APL \[[@CR48]\] (Fig. [4](#Fig4){ref-type="fig"}). Variant chromosomal translocations \[*t*(11;17) or *t*(5;17)\] can be detected in no more than 2% of all APL patients. The presence of additional chromosomal abnormalities was further shown to have no affect on the clinical outcomes, including 17p or other adverse karyotypes known to confer poor outcome in AML \[[@CR49]\].Fig. 4APL is characterized by a specific balanced reciprocal translocation *t*(15;17) that fuses the *PML* gene on chromosome 15 to the *RARα* gene on chromosome 17

The HL60 cell line, established in 1977 from a patient with AML \[[@CR50]\], was long considered to be a promyelocytic cell line. HL60 cultures comprise maturation-arrested cells with many properties that are similar to those of promyelocytes. The cells can be induced to differentiate terminally in vitro, and some reagents such as retinoic acid cause HL60 cells to differentiate to granulocyte-like cells. The HL60 cell genome contains an amplified c-myc proto-oncogene, which declines following induction of differentiation. However, the use of the HL60 cell line as a biological model has actually confused the field for many years, and HL60 cells differ from promyelocytes in many respects \[[@CR51]\]. A re-evaluation of the original specimens indicated that FAB class M2 would have been a more accurate description \[[@CR52]\]. Cytogenetic analysis showed the occurrence of many karyotypic abnormalities, but HL60 cells do not express PML-RARA.

During this period, anthracycline-based chemotherapies cured some patients with APL, raising hopes. At the genetic level, APL was found to correspond to a unique *t*(15;17) chromosomal translocation.

All-*Trans* Retinoic Acid Era {#Sec4}
=============================

The Beginnings of ATRA Therapy {#Sec5}
------------------------------

Some evidence emerged in the 1960s that led to the development of cancer differentiation therapy \[[@CR53]\]. A major breakthrough was made by Sachs, who discovered in 1978 that leukemia cells could undergo differentiation upon the influence of various agents \[[@CR54]\]. In the early 1980s, a wide variety of compounds, including retinoic acid, were shown to induce morphologic and functional maturation of HL-60 cells \[[@CR55]\], and a specific response of APL specimens \[[@CR56]\]. The first cases relating to the clinical effects of retinoic acid as a differentiating inducer of APL were reported \[[@CR57], [@CR58]\]. Flynn et al. induced in vitro maturation of leukemic promyelocytes from a patient with APL refractory to chemotherapy, and showed that similar maturation occurred in vivo after oral treatment with 13-*cis*-retinoic acid \[[@CR57]\]. Nilsson reported that blood and marrow were normalized through differentiation induction by oral 13-*cis*-retinoic acid in one relapsing APL patient who was resistant to further lines of chemotherapy \[[@CR58]\]. Daenen et al. administered 13-*cis*-retinoic acid to an APL patient who could not be treated with intensive chemotherapy because of invasive aspergillosis. The patient achieved CR with the disappearance of signs of coagulopathy \[[@CR59]\]. During the same period, given the results achieved in Western medicine using cancer differentiation therapy and noting one of Confucius's famous analects ("If you use laws to direct the people, and punishments to control them, they will merely try to evade the laws, and will have no sense of shame. But if by virtue you guide them, and by the rites you control them, there will be a sense of shame and of right."), in 1980 physicians at the Shanghai Rui Jin Hospital started to screen APL patients for differentiation inducers \[[@CR60]\]. ATRA, an isomer of retinoic acid, was shown to be superior to 13-*cis*-retinoic acid in both in vitro and in vivo settings and to strongly induce terminal differentiation in HL-60 and fresh APL cells. In 1985, a meeting held in Paris on differentiating agents discussed the specific activity of ATRA in APL, and resulted in a close collaboration between the Shanghai Institute of Hematology and the Saint-Louis Hospital in Paris focusing on the use of ATRA manufactured by Pharmaceutical Unit Number 6 in Shanghai. ATRA was first employed to treat APL patients in 1985 at the Rui Jin Hospital in Shanghai. The first patient treated with ATRA was a 5-year-old girl treated in 1985 at the Shanghai Children's Hospital after the failure of anthracycline-based chemotherapy. She received ATRA at 45 mg/m^2^/day and achieved CR 3 weeks later \[[@CR60]\]. After isolated case reports (4 newly diagnosed and 2 refractory to chemotherapy) were published in 1987 \[[@CR61]\], Huang et al. reported that treatment with ATRA alone was successful in 24 APL patients (16 newly diagnosed and 8 refractory cases) with more than 90% CR and no exacerbation of coagulopathy or early death due to hemorrhage \[[@CR62]\]. Despite these positive results, Western pharmaceutical companies refused to manufacture ATRA, which was instead obtained from the Chinese for the treatment of French APL patients. Finally, following the presentation of the results of ATRA treatment at the Memorial Sloan Kettering Cancer Center in 1989 and the intervention of Raymond Warrell, Roche Nutley began to manufacture ATRA tablets \[[@CR63]\]. The efficacy of ATRA was confirmed in Paris for APL patients experiencing a first or subsequent relapse \[[@CR64], [@CR65]\]. CR was achieved in 95% of cases with no aplasia, no alopecia, and few infection episodes. The most striking feature was the gradual terminal differentiation of leukemic cells in the bone marrow, combined with the presence of Auer rods in mature granulocytes \[[@CR65], [@CR66]\]. In the US, the first report of an APL patient responding to ATRA was published in 1991 \[[@CR67]\]. However, ATRA alone could not induce prolonged remission. Despite being associated with a high rate of CR, the use of ATRA alone caused progressive resistance to the drug, leading to relapse with 3 to 6 months. This was suggested to be caused by a reduction in the plasma concentration of ATRA due to accelerated clearance \[[@CR64], [@CR68], [@CR69]\].

At that time, this new approach regarding APL treatment was not unanimously accepted, and divergent opinions were expressed---notably in a provocative editorial in which the idea that APL was a pseudoleukemia was explored \[[@CR70]\].

Advances in Molecular Biology {#Sec6}
-----------------------------

The molecular basis for the response to ATRA was elucidated in the early 1990s \[[@CR71]--[@CR74]\]. The breakpoint on 17q21 was located within the locus of the retinoic acid receptor alpha (*RARA*) gene \[[@CR75]\]. An unusual pattern of RARA mRNA was found in blast cells from APL patients \[[@CR76]\]. The breakpoint on the*RARA* gene was cloned and sequenced using the NB4 cell line (established by Lanotte \[[@CR77]\]) and fresh APL cells \[[@CR71]--[@CR73]\]. Its partner gene located in the breakpoint region on chromosome 15q22 was the promyelocytic leukemia (*PML*) gene (originally named *MYL*), sequenced 1 year later \[[@CR78], [@CR79]\]. This gene was subsequently shown to be involved in the control of cell proliferation, apoptosis, and senescence \[[@CR80]\]. Meanwhile, the cloning of the *t*(15;17) translocation enabled reverse transcription polymerase chain reaction (RT PCR)-based strategies for the rapid diagnosis and sensitive detection of minimal residual disease (MRD) \[[@CR81]--[@CR85]\]. However, the initial interlaboratory sensitivity variations constituted a major limitation. Persistence or reappearance of PCR positivity for PML/RARA in patients with morphological remission was correlated with impending hematologic relapse \[[@CR84]\]. This allowed the identification of patients requiring treatment intensification \[[@CR86], [@CR87]\] and permitted the kinetics of response and disease relapse to be determined with the development of real-time quantitative PCR of PML/RARA detection \[[@CR88]\]. The biochemical mechanisms of transcriptional repression induced by PML/RARA protein and the molecular basis for the response to ATRA were later identified \[[@CR89]--[@CR91]\]. Variant translocations were subsequently discovered \[[@CR92]\]. These variant fusion genes are clinically significant due to their differential responses to ATRA. Some of these variants are relatively or completely resistant to ATRA, such as *t*(11;17) (q23;q21) (leading to the *PLZF*-*RARA* fusion gene \[[@CR93], [@CR94]\]) and the fusion gene between *STAT5b* and *RARA* \[[@CR95]\]. Other types are sensitive to ATRA, such as *t*(11;17) (q13;q21) \[[@CR96]\], *t*(5;17) (q35;q21) \[[@CR97]\], and *t*(4;17) (q12;q21) \[[@CR98]\], leading to the fusion genes *NuMA*-*RARA*, *NPM1*-*RARA*, and *FIP1L1*-*RARA*, respectively. Approximately 10 diverse translocation partner genes of *RARA* have now been reported \[[@CR99]\]. The nature of the fusion partner has a significant bearing upon the disease characteristics, including sensitivity to therapy, demanding a highly specific treatment approach.

Intensive Anthracycline-Based Chemotherapy in Combination with ATRA {#Sec7}
-------------------------------------------------------------------

Based on the first results with ATRA alone, French clinicians initiated a combination therapy consisting of ATRA alone until CR was achieved, followed by three courses of daunorubicin and cytarabine \[[@CR100]\]. Twenty-six patients entered this nonrandomized study. Results, which were compared to a historical control group, showed a reduction in the early relapse rate as compared with ATRA treatment alone but a similarly low number of late relapses. In 1991, the European APL group launched the first randomized trial comparing three courses of chemotherapy with daunorubicin plus cytarabine versus ATRA until CR achievement followed by the same three courses of chemotherapy. The trial was stopped prematurely because event-free survival (EFS) was significantly better in the ATRA arm (12-month EFS: 79% versus 50%) \[[@CR101]\]. In the ATRA group, the 4-year EFS was 63% compared to 17% in the chemotherapy-only cohort. These results were later confirmed by those from the North American Intergroup (5-year DFS: 69% versus 29%) \[[@CR5], [@CR102]\]. In a second randomized study (APL93 trial), the European APL group demonstrated that concurrent ATRA plus chemotherapy (daunorubicin plus cytarabine) resulted in a significantly lower 2-year relapse rate (6% versus 16%) when compared with sequential ATRA followed by chemotherapy \[[@CR103]\]. This was further confirmed by other multicenter trials \[[@CR6], [@CR104]--[@CR106]\]. The early addition of chemotherapy also decreased the incidence of retinoic acid syndrome \[[@CR107]\]. Two randomized studies (the APL93 trial in Europe and the US Intergroup trial) tested the effects of maintenance therapy in APL \[[@CR102], [@CR103]\]. The European trial showed that maintenance for 2 years with intermittent ATRA therapy (2 weeks every 3 months) combined with low-dose chemotherapy (6-mercaptopurine daily plus methotrexate weekly) reduced the risk of relapse, while the US trial demonstrated that patients who had not received ATRA during induction benefited from ATRA used as maintenance therapy. However, two subsequent studies did not show any benefit of maintenance therapy in APL patients achieving molecular CR \[[@CR108], [@CR109]\]. New approaches to maintenance therapy were investigated, such as the use of tamibarotene (formerly Am80), which showed a trend for improved efficacy in high-risk APL patients \[[@CR110]\]. The incidence of central nervous system (CNS) involvement in first relapse has been estimated to be 2%, with a higher prevalence in high-risk patients (5.5%) \[[@CR111]\]. There is a general consensus for no CNS prophylaxis in low- and intermediate-risk patients \[[@CR111]--[@CR113]\] and CNS prophylaxis in high-risk patients and those experiencing CNS bleeding at diagnosis or during induction \[[@CR111]\].

Overall, it became apparent during this period that APL was a curable disease when using a combination of ATRA and chemotherapy, and autologous or allogeneic stem cell transplantation was no longer indicated for first-line therapy. Long-term outcomes in large series showed a 5-year EFS of 70%, a 6-year DFS of 68%, and the best outcomes were seen in patients receiving ATRA during induction and consolidation.

Mechanisms of Action of ATRA {#Sec8}
----------------------------

Reactivation of *PML*-*RARA*-repressed transcription by retinoic acid was proposed to explain the induction of differentiation and clearance of APL. PML-RARA is able to form homodimers that repress the transcriptional expression of target genes involved in granulocytic differentiation by binding to a set of retinoic acid response elements in the regulatory regions of these genes and recruiting corepressor proteins on both PML and RARA moieties \[[@CR60]\]. PML-RARA can also recruit methylating enzymes, leading to hypermethylation of the downstream gene promoter, resulting in aberrant epigenetic control at critical gene chromatin domains. A pharmacological ATRA concentration of 10^−6^--10^−7^ M is generally considered to cause a change in PML-RARA configuration. The corepressor complex dissociates from the receptor and a coactivator complex is recruited, opening the chromatin structure and relieving transcriptional repression. There is modulation of a large number of genes involved in granulocytic differentiation \[[@CR114]\]. Over the years, a number of reports have questioned this model of retinoic acid-mediated induction of differentiation \[[@CR115]\]. Another effect of ATRA is to induce PML-RARA degradation by triggering caspase-mediated cleavage of the PML-RARA chimeric protein \[[@CR116]\] and through a ubiquitin/proteasome system-mediated degradation \[[@CR117]\].

Differentiation Syndrome {#Sec9}
------------------------

Differentiation syndrome is a clinical syndrome caused by ATRA-induced differentiation. During treatment, patients presented an increased WBC count, potentially associated with unexplained fever, hypotension, weight gain, respiratory distress, pulmonary infiltrates, pleural and/or pericardial effusions, and renal failure \[[@CR65]\]. These disorders were defined as ATRA syndrome \[[@CR118]\], and involved one-third of the patients treated in Western countries \[[@CR119]\] but a smaller proportion of those treated in China \[[@CR120]\]. The risk is greatest in patients with already high WBC counts. The pathogenesis is not well defined. However, a systemic inflammatory response driven by the release of pro-inflammatory cytokines, capillary leakage, and alterations in cellular adhesion molecule expression leading to tissue infiltration by leukemic cells and microcirculation occlusion was hypothesized \[[@CR121], [@CR122]\]. The standard management consists of dexamethasone 10 mg twice daily intravenously until resolution and for at least 3 days \[[@CR112]\]. Prophylactic steroid therapy during induction can reduce the incidence of differentiation syndromes \[[@CR123]--[@CR125]\].

Risk-Adapted Treatment {#Sec10}
----------------------

Based on their initial studies, the Italian GIMEMA group (Gruppo Italiano per le Malattie Ematologiche dell'Adulto) and the Spanish PETHEMA group (Programa Espanol para el Tratamiento de las Hemopatias Malignas del Adulto) questioned the role of cytarabine in the treatment of APL and used only an anthracycline for chemotherapy in combination with ATRA for remission induction followed by chemotherapy consolidation and maintenance therapy \[[@CR6], [@CR105], [@CR126]\]. The GIMEMA group proposed an ATRA/idarubicin (AIDA) induction and added three cycles of consolidation including idarubicin, cytarabine, etoposide, mitoxantrone, and thioguanine. The AIDA0493 protocol showed that 95% of patients achieved CR, a 2-year EFS of 79%, and a 2-year overall survival (OS) of 87% \[[@CR105], [@CR126]\]. The PETHEMA LPA96 trial demonstrated that removing all non-anthracycline drugs from the consolidation phase after an AIDA induction did not significantly affect patient outcomes \[[@CR6]\]. This was confirmed by the Australasian Leukaemia and Lymphoma Group (ALLG) APML3 trial, which used an AIDA induction and an additional second cycle of idarubicin and demonstrated the importance of maintenance therapy in this setting \[[@CR127]\]. The AIDA regimen then became one of the most popular standard treatments for newly diagnosed APL, and formed the basis for a meta-analysis leading to a proposed score for relapse risk assessment (Table [2](#Tab2){ref-type="table"}) that was used in further trials \[[@CR128]\]. The LPA99 PETHEMA trial evaluated consolidation therapy with ATRA plus three chemotherapy courses based on intensified idarubicin doses for patients with intermediate- and high-risk APL. Compared to the previous LPA96 trial, this schedule reduced the 3-year cumulative incidence of relapse (9% versus 20%) and significantly improved disease-free survival and overall survival \[[@CR129]\]. In the LPA2005 trial, treatment of high-risk patients with cytarabine significantly reduced the 3-year relapse rate from 26% to 11% when compared to the results from the LPA99 trial \[[@CR129], [@CR130]\]. Similarly, the AIDA2000 trial showed that a risk-adapted strategy in consolidation resulted in better long-term outcomes by avoiding toxicity and infection in low- and intermediate-risk APL patients \[[@CR4]\]. The French APL2000 trial showed a benefit of cytarabine in consolidation for high-risk patients and an increased risk of relapse when omitting cytarabine from induction and consolidation courses \[[@CR131], [@CR132]\]. A review of these results in combination with those from the LPA99 trial confirmed a benefit for an ATRA-idarubicin-based protocol in low- and intermediate-risk patients and better survival with the combination anthracycline-cytarabine in high-risk patients \[[@CR3]\]. In contrast, the British Medical Research Council (MRC) AML15 study reported an increased number of deaths in CR when cytarabine was administered, but this did not translate into significant differences in terms of survival rates \[[@CR133]\]. No studies have directly compared the type of anthracycline used. A matched-pair analysis comparing idarubicin and daunorubicin showed no significant difference \[[@CR134]\]. However, anthracycline-related cardiotoxicity is a major concern \[[@CR135]\], especially in patients treated with an AIDA-based protocol, who showed diastolic dysfunction and regional wall motion abnormalities \[[@CR136]\].Table 2Risk stratification in APLRisk categoryWBC (× 10^9^/L)Platelets (× 10^9^/L)Low risk≤ 10\> 40Intermediate risk≤ 10≤ 40High risk \> 10*WBC* white blood cells

Overall, these results led the European LeukemiaNet to recommend that APL be treated with an ATRA/anthracycline combination for induction, two or three cycles of anthracycline-based chemotherapy as consolidation, intermediate- or high-dose cytarabine in younger patients with WBC count \> 10 × 10^9^/L, and maintenance therapy for protocols in which it has been shown to be beneficial \[[@CR112]\].

Relapse After Treatment with ATRA {#Sec11}
---------------------------------

About 20% of patients have been reported to relapse after risk-adapted ATRA and chemotherapy regimens \[[@CR137]\]. Several studies have shown the clinical benefit of early identification of disease recurrence and pre-emptive therapy at the time of molecular relapse \[[@CR87], [@CR138], [@CR139]\]. Molecular relapse is conventionally defined as two consecutive RT-PCR positive tests in marrow samples collected 2--4 weeks apart after first-line therapy. Treatment of molecular relapse was associated with a better treatment tolerance, fewer days of hospitalization, fewer early deaths, and a reduced rate of differentiation syndrome. In the case of a relapse after first-line therapy using ATRA, a second remission can be achieved in approximately 90% of cases with the use of ATRA plus chemotherapy. A subsequent allogeneic or autologous HSCT was then recommended to avoid another relapse \[[@CR140]--[@CR142]\]. In 2009, an expert panel on behalf of the European LeukemiaNet published recommendations for the management of relapsed APL based on literature data and the recent introduction of ATO in this situation \[[@CR112]\]. Two cycles of ATO ± ATRA therapy were considered the best option for patients who relapsed after ATRA and chemotherapy regimens. In patients achieving molecular remission, intensification with autologous SCT was recommended, or prolonged ATO-ATRA therapy. Allogeneic HSCT was recommended for patients who failed to achieve molecular remission or for those who relapsed after less than 1 year of first CR. Central nervous system prophylaxis is usually recommended at relapse.

Mutation Landscape and Other Prognostic Factors {#Sec12}
-----------------------------------------------

*FLT3* emerged as the most frequently altered gene in primary APL; 27% of cases had *FLT3*-*ITD* and 16% of cases had *FLT3*-*TKD* mutations \[[@CR143]\]. While AML with *FLT3*-*ITD* is associated with a high risk of relapse, its clinical impact in APL is still controversial \[[@CR144]--[@CR146]\]. *FLT3*-*ITD* was associated with high-risk groups and therefore independently associated with inferior OS. A meta-analysis of patients treated predominantly with ATRA and chemotherapy identified lower rates of DFS and OS in patients with a *FLT3*-*ITD* mutation \[[@CR147]\]. The presence of a *FLT3* mutation also appeared to increase the risk of induction death \[[@CR148], [@CR149]\]. However, this was not confirmed in patients who received ATO or ATRA-ATO \[[@CR146]\]. Other commonly observed mutated genes included *WT1* (14%), *NRAS* (10%), *KRAS* (4%), *ETV6* (1%), and *EZH2* (1%). *DNMT3A*, *NPM1*, *TET2*, *IDH1*, *IDH2*, and *ASXL1* mutations were absent or rarely observed.

Immunophenotyping might also play a role in prognostication. CD56 overexpression (10% of APL cases) is associated with a high WBC count and an increased risk of relapse \[[@CR150]\]. CD2, found in 24% of APL patients, was associated with CD34 positivity, a higher WBC count, Bcr3, and a microgranular subtype \[[@CR151]\].

The mechanism of *PML*-*RARA*-induced oncogenic transformation has been studied using various APL mouse models \[[@CR152], [@CR153]\]. *PML*-*RARA* is the only genetic event capable of initiating typical APL disease when expressed in transgenic mice. Additional genetic/epigenetic changes play a role in progression to full transformation in the APL phenotype. The recent identification of crucial *PML*-*RARA* features has resulted in a complex image of APL pathogenesis. The *PML*-*RARA* fusion protein appears to be multifaceted, deregulating the differentiation and self-renewal of myeloid progenitors and conferring resistance to apoptosis. Heterotetramers of *PML*-*RARA* bound to RXRA allow specific binding to a large variety of DNA sites, including sites recognized by nuclear receptors controlling myeloid differentiation or stem cell self-renewal \[[@CR154], [@CR155]\]. *PML*-*RARA* undergoes post-translational modifications, such as PML sumoylation and RARA phosphorylation, which are important for APL initiation \[[@CR156], [@CR157]\]. Furthermore, RARA fusion proteins interact with key chromatin remodeling complexes, which play a crucial role in stem cell maintenance \[[@CR158]\]. While translocations of *RARA*, typically *PML*-*RARA*, are a genetic hallmark of APL, a small fraction of APL cases lack translocations of *RARA*. Retinoic acid receptors (RARs) are nuclear hormone receptors which function as ligand-activated transcription factors that interact specifically to modulate transcription DNA elements \[[@CR159]\]. RARs include alpha (*RARA*), beta (*RARB*), and gamma (*RARG*) receptor types. They function as heterodimers with retinoid X receptors (RXRs). Translocations involving *RARB* and *TBLXR1*-*RARB* have been identified \[[@CR160]\]. TBLXR1-RARB homodimerizes and diminishes transcriptional activity for the RAR pathway in a dominant-negative manner. However, the response of APL with *RARB* translocation to retinoids was attenuated compared with that of *PML*-*RARA*. The involvement of *RARG* in a chimeric fusion transcript (*NUP98*) has also been reported \[[@CR161]\]. Heterodimers formed by *RXRA*-*RARG* are necessary for growth arrest and visceral and primitive endodermal differentiation \[[@CR162]\]. Artificial *PML*-*RARG* fusion proteins are able to produce the same biological effects as those mediated in the cells by *PML*-*RARA* and to confer responsiveness to differentiation treatment \[[@CR162]\]. Inoculated transduced cells expressing *PML*-*RARG* were able to trigger leukemia in murine models \[[@CR159]\].

Overall, the introduction of ATRA in 1985 to improve the response of APL patients to chemotherapy has led to a revolution in the prognosis of this disease.*PML*-*RARA* fusion was shown to be the only constant genomic abnormality in APL cells.

Arsenic Trioxide {#Sec13}
================

Arsenic, An Old Remedy {#Sec14}
----------------------

Arsenic is one of the oldest drugs, and has been used to treat a variety of diseases. It was mentioned by Hippocrates (460--370 BC), who used realgar and orpiment pastes to treat ulcers. Arsenic was also used to treat diseases in ancient China ("Fight poison with poison"). It is mentioned in the Chinese Nei Jing treaty (263 BC) as a treatment for periodic fever; Hong Ge (284--364 AD used it as a disinfectant; Si-Miao Sun (581--682 AD) used it to treat malaria, and Shi-Zhen Li (1518--1593 AD) administered it for a variety of diseases \[[@CR163], [@CR164]\]. In Western countries, it was used by Avicenna (980--1037 AD) and Paracelsus (1493--1541 AD). In 1774, Lefébure proposed an arsenic-containing paste as a "remedy to radically cure all cancers" \[[@CR165]\]. Fowler's solution containing 1% potassium arsenite, first described in 1845, was one of the first chemotherapeutic agents used in the treatment of leukemia \[[@CR166]--[@CR168]\]. It was rediscovered by Forkner and Scott in 1931 for the treatment of chronic myeloid leukemia (CML) \[[@CR168]\]. In China, the use of arsenic to treat leukemia started in the early 1970s. Tai Yun Han, a pharmacist from Harbin Medical University, made solutions (named Ailing solutions) using the same components as those in an old anticancer remedy: ATO, mercury chloride, and toad venom. His colleague, Ting Dong Zhang, explored the effect of the solution on myeloid leukemia patients and observed some promising effects \[[@CR164]\].

First Trials with ATO {#Sec15}
---------------------

There are three inorganic forms of arsenic: red arsenic (AS~4~S~4~, also known as realgar), yellow arsenic (AS~2~S~3~, also known as orpiment), and white arsenic or ATO (AS~2~O~3~), which is made by burning realgar or orpiment \[[@CR60]\]. In 1992, Sun et al. reported that CR was achieved in 21 of 32 APL patients treated with a solution of ATO \[[@CR169]\]. The survival rate was 30% after 10 years. Results obtained using pure ATO were reported in the late 1990s: CR rates of 73% and 52% were obtained in 30 newly diagnosed and 42 relapsed APL cases, respectively \[[@CR170]\]; CR was achieved in 9 of 10 patients treated with ATO alone and in 5 patients treated with a combination of ATO and low-dose chemotherapy or ATRA \[[@CR171], [@CR172]\]. These results were further confirmed by a group of 47 relapsed and 11 newly diagnosed APL cases with CR rates of 85 and 73%, respectively \[[@CR173]\]. In a retrospective study of 242 cases from Harbin Medical University Hospital, the CR rates in newly diagnosed patients and relapsed patients were 88% and 60%, respectively, with a 5-year OS of 92% and a 7-year OS of 77% \[[@CR174]\]. Furthermore, molecular remission was reported in a high proportion of patients (72--91%) who received ATO alone \[[@CR175], [@CR176]\]. Based on those results, ATO was introduced by many groups worldwide for the treatment of relapsed APL. ATO-based salvage therapy has been able to induce long-lasting remission. The main studies reported in Table [3](#Tab3){ref-type="table"} \[[@CR175]--[@CR186]\] were reviewed by Lengfelder et al. \[[@CR187]\].Table 3Studies in which ATO was used in relapsed APL casesReferenceNo. of patientsCR\
Days to CRRD\
EDPost-inductionSurvivalShen et al. \[[@CR172]\]1593%38 (28--54)^a^7%0ATO (1c)\> 80% (1.5y)Soignet et al. \[[@CR175]\]5287%(24--85)12%1%ATO (5c)Auto (3), Allo (14)66% (1.5y)Niu et al. \[[@CR173]\]4785%316%9%ATO ± CT or CT50% (2y)Shen et al. \[[@CR177]\]2080%ND10%10%DNR62% (2y)Kwong et al. \[[@CR178]\]8100%4500IdaNDLeoni et al. \[[@CR179]\]786%(20--40)014%HD-AraC, MTZAuto (2), Allo (2)\> 80% (2y)Ohnishi et al. \[[@CR180]\]1479%43 (27--60)14%7%ATO (1c), CT ± ATRAAllo (2)NDLazo et al. \[[@CR181]\]12100%52 (27--75)00ATO (4c) ± CTAllo (1)NDRaffoux et al. \[[@CR182]\]2080%42 (14--86)10%10%ATO (1--2c) ± ATRAAuto (1), Allo (7)59% (2y)Carmosino et al. \[[@CR183]\]1173%38 (28--50)027%ATO (1c) ± ATRA ± IdaAuto (2), Allo (2)NDShigeno et al. \[[@CR176]\]3491%46 (26--60)6%3%ATO (1c) ± CT + ATRAAuto (1), Allo (9)56% (2y)Thomas et al. \[[@CR184]\]2584%498%8%ATO (1c) ± CT, MTAuto (9), Allo (3)77% (2y)Aribi et al. \[[@CR185]\]8100%39 (21--56)00ATO (5c) + ATRA + GO, MTAllo (1)75% (3y)Alimoghaddam et al. \[[@CR186]\]3177%3010%13%ATO (1--4c)81% (2y)*ATO* arsenic trioxide, *ATRA* all-*trans* retinoic acid, *Allo* allogeneic stem cell transplantation, *Auto* autologous stem cell transplantion, *c* courses, *CR* complete remission, *CT* chemotherapy, *DNR* daunorubicin, *ED* early death, *GO* gemtuzumab ozogamicin, *Ida* idarubicin, *MT* maintenance therapy, *MTZ* mitoxantrone, *RD* resistant disease, *y* years^a^Median (range)

Mechanisms of Action {#Sec16}
--------------------

At the time that the efficiency of arsenic for the treatment of APL was first reported, the prevalent concept was that terminal blast differentiation drove the response to ATRA. ATO was proposed to initiate apoptosis or partial differentiation \[[@CR171]\]. ATO was shown to exert dose-dependent effects on APL cells \[[@CR171]\]. At high concentrations (0.5--2.0 μmol/L), ATO induced apoptosis, mainly by activating the mitochondria-mediated intrinsic apoptotic pathway. At lower concentrations (0.1--0.5 μmol/L), ATO promoted the differentiation of APL cells. This was supported by animal models and the examination of bone marrow in APL patients treated with ATO \[[@CR188]\]. The pro-apoptotic activity of ATO was then scrutinized at the gene and protein levels, and various involvements were noted, including a pathway composed of *ATR*, *PML*, *Chk2*, and *p53* \[[@CR189]\]. Critically, arsenic does not activate RARA-dependent transcription \[[@CR165]\], although it may induce differentiation syndrome in APL patients \[[@CR190]\]. Subsequent research has shown that ATO's therapeutic efficacy is due to its effect on the PML moiety of the PML-RARA fusion protein \[[@CR2]\]. The PML protein is important for the formation of nuclear bodies (first described as electron-dense shells with electron-light cores in 1960 \[[@CR191]\]), which allow the recruitment and interaction of proteins through the posttranslational modification processes of sumoylation and ubiquitination. PML-RARA expression disrupts PML nuclear bodies. Disruption of nuclear bodies leads to the loss of their tumor-suppressive activity, possibly contributing to leukemogenesis. The binding of arsenic to the PML component through two cysteine residues induces their oxidation and the formation of a disulfite bond \[[@CR192], [@CR193]\]. In the final step, ATO mediates the recruitment of 11S proteasome, a process essential for the degradation of PML and PML-RARA proteins \[[@CR188], [@CR194], [@CR195]\]. PML-RARA destruction also abrogates self-renewal through the re-formation of PML nuclear bodies that were initially disassembled by PML-RARA and subsequent p53 activation \[[@CR196]\]. The engagement of prosenescent responses explains why single-agent arsenic is definitively curative in up to 70% of patients, while ATRA alone only yields transient responses \[[@CR197], [@CR198]\]. In mouse models, the presence of PML and p53 is absolutely required for a long-term therapy response \[[@CR196]\]. Failure of therapy in vivo is likely due to the lack of p53 activation, which occurs only when PML-RARA is efficiently degraded. Mutations in the unrearranged PML allele that affect arsenic binding were found in patients resistant to therapy \[[@CR199]\]. Additionally, arsenic induces the degradation of PML/PML-RARA through the production of reactive oxygen species (ROS). Anthracyclines, which can stimulate the production of ROS, may also contribute to PML-RARA degradation \[[@CR200]\]. As opposed to ATRA, there is evidence for the eradication of leukemia-initiating cells after ATO therapy \[[@CR115]\]. There is also evidence that ATO crosses the blood--brain barrier. The concentration of arsenic in the cerebrospinal fluid has been shown to correlate with the plasma level \[[@CR201]\]. Resistance to ATO is uncommon, but can be due to various reasons. Missense mutations in the PML-RARA transcripts have been identified in patients resistant to ATO \[[@CR202]\].

ATO Toxicities {#Sec17}
--------------

Despite the quick resolution of significant coagulation disturbances, severe hemorrhage was the most frequent cause (70%) of early death, with most of the fatal bleeding events located in the CNS \[[@CR175]\]. Differentiation syndrome (retinoic-acid-like syndrome) is relatively common (reported in 7--35% of cases) and potentially life-threatening complication occurring during the first days or weeks of treatment. Preventive treatment is particularly important in high-risk patients (patients with a WBC count \> 10 × 10^9^/L). Treatment includes the prompt use of intravenous dexamethasone 10 mg twice daily until resolution or for a minimum of 3 days \[[@CR122]\]. Hyperleukocytosis can be managed using hydroxyurea \[[@CR8]\]. In the AML17 study, patients with a peripheral WBC count \> 10 × 10^9^/L at baseline received gemtuzumab ozogamicin (GO) 3 mg/m^2^ on day 1 and again on day 4 if the WBC count had not fallen below this value \[[@CR7]\]. QTc prolongation is a common side effect of ATO. It can lead to torsade de pointes-type ventricular arrhythmia, which is potentially fatal \[[@CR8]\]. Patients with a prolonged QTc interval above 500 ms are recommended to maintain adequate potassium and magnesium concentrations. QTc prolongation has recently been the subject of a study that aimed to identify the optimal correction formula to be employed in QTc calculations \[[@CR203]\]. Hepatic toxicity has frequently been reported in studies employing ATO, especially in terms of an increase in liver enzymes \[[@CR197]\]. Although frequent, this complication is usually reversible and successfully managed with the temporary discontinuation of ATO. Neurological toxicity, mainly consisting of peripheral neuropathy, has also been reported. This mild side effect is usually managed with temporary discontinuation. An unsolved issue is whether or not CNS prophylaxis is needed. Pharmacodynamic studies indicated that one-third of the ATO crosses the blood--brain barrier, which could suggest that a sufficient amount of the drug is available on site to prevent disease recurrence \[[@CR204]\]. No arsenic accumulation or delayed toxicity was observed in patients followed up for over 10 years \[[@CR205], [@CR206]\].

ATO in Newly Diagnosed APL {#Sec18}
--------------------------

Two therapeutic approaches were used with ATO in newly diagnosed APL: (1) minimizing or eliminating cytotoxic chemotherapy from induction and consolidation phases; (2) reinforcing the antileukemic efficacy of the ATRA plus chemotherapy regimen.

The main studies that have evaluated ATO-based induction and consolidation phases are shown in Table [4](#Tab4){ref-type="table"}. In noncomparative prospective studies, ATO was used as a monotherapy for induction and prolonged consolidation or as maintenance therapy \[[@CR197], [@CR198]\]. The CR rate was 86% and the early death rate (mostly due to fatal hemorrhages) was 14%. In one study, the 5-year OS estimate and the 5-year DFS estimate were 74% and 80%, respectively \[[@CR198]\]. In the other, the OS and DFS estimates after a median follow-up of 38 months were 64% and 67%, respectively \[[@CR197]\]. In relapsing patients, a second CR was achieved in 52% of cases when treated with ATO again, albeit with a 2-year survival rate of only 35% \[[@CR197]\]. Another trial combined ATO and ATRA, extended with GO, and idarubicin when the WBC count was above 10 × 10^9^/L \[[@CR207], [@CR208]\]. A randomized study comparing ATO monotherapy, ATO plus ATRA, and ATRA monotherapy as the induction regimen was conducted in China \[[@CR205]\]. Induction was followed by consolidation and maintenance therapy. The CR rates ranged from 90 to 95% among the three treatment arms, and a shorter time was needed to reach CR and PML-RARA negativity with combination therapy. The 5-year OS and the 5-year EFS were 92% and 89%, respectively.Table 4Studies using ATO for remission inductionReferenceNo. of patientsATO doseCR (%)mCR (%)OSRavandi et al. \[[@CR208]\]820.15 mg/kg+ ATRA ± GO ± Ida9173^a^85% (3y)Hu et al. \[[@CR205]\]850.16 mg/kg+ ATRA94100^a^92% (5y)Mathews et al. \[[@CR198]\]7210 mg8676^b^74% (5y)Ghavamzadeh et al. \[[@CR197]\]1970.15 mg/kg8692^c^64% (5y)Post-induction therapy: 4 courses of ATO + ATRA ± GO \[[@CR208]\]; 3 cycles of chemotherapy followed by maintenance therapy \[[@CR205]\]; 7 courses of ATO \[[@CR198]\]; 4 courses of ATO \[[@CR197]\]*ATO* arsenic trioxide, *ATRA* all-*trans* retinoic acid, *CR* complete remission, *GO* gemtuzumab ozogamicin, *mCR* molecular complete remission, *OS* overall survival, *y* years^a^After consolidation^b^After induction^c^During follow-up

To reduce chemotherapy exposure, the role of ATO in consolidation has been investigated. A significant benefit of the ATO-ATRA-chemotherapy arm was demonstrated in a randomized study from the US Intergroup in comparison with the ATRA-chemotherapy arm \[[@CR209]\]. Patients who achieved a CR after ATRA and chemotherapy were randomized to receive either additional ATO consolidation (two cycles at 0.15 mg/kg/day for 5 days for 5 weeks) or two cycles of a common ATRA/daunorubicin consolidation. The results demonstrated that for all risk groups, ATO in consolidation significantly improved 3-year DFS (90% vs 70%; *P * \< 0.0001), and there was a nonstatistically significant improvement in terms of OS. In another American study, some of the chemotherapy cycles were replaced with ATO cycles \[[@CR210]\]. Comparable outcomes were reported, with a DFS of 90% and an OS of 88%. The APL 2006 study showed that cytarabine can be replaced by ATO without altering the relapse rate in the low/intermediate-risk group, while the combination increased myelosuppression in the high-risk group \[[@CR211]\].

The use of ATO improved the clinical outcomes of refractory or relapsed as well as newly diagnosed APL. ATO appears to be the most effective single agent for APL. ATO cures APL by initiating PML-RARA oncoprotein degradation by targeting its PML moiety.

Chemotherapy-Free Treatment in APL {#Sec19}
==================================

ATRA-ATO in Frontline Therapy {#Sec20}
-----------------------------

Following studies in a mouse model by the group led by de Thé \[[@CR212]\] and that led by Waxman \[[@CR213]\], which showed that the ATRA-ATO combination could dramatically prolong survival and even eradicate disease in animals, the group from the Shanghai Institute of Hematology was the first to report on the use of the ATRA-ATO combination in a cohort of 85 newly diagnosed APL patients \[[@CR205], [@CR214]\]. CR was achieved in 94% of cases and the 5-year EFS and OS were 89% and 92%, respectively. Subsequently, several groups reported the use of ATRA/ATO in newly diagnosed patients \[[@CR7], [@CR8], [@CR207], [@CR208], [@CR215], [@CR216]\] (Table [5](#Tab5){ref-type="table"}). The MD Anderson group treated 187 patients with this combination in a nonrandomized trial \[[@CR215]\]. Patients with high-risk APL as well as those in low- or intermediate-risk groups who developed leukocytosis during ATRA/ATO therapy were given a dose of GO. CR was achieved in 96% of cases with a 5-year OS of 89 and 86% in low-risk and high-risk APL, respectively. The final report of the randomized Italian-German APL0406 trial confirmed the efficacy and safety of the ATRA/ATO combination, especially in the low-risk APL group \[[@CR216]\]. In this study, 263 patients with newly diagnosed non-high-risk APL were randomly assigned to ATRA/ATO and ATRA/chemotherapy arms \[[@CR8]\]. CR rates of 100% and 97% were reported in the ATRA/ATO and ATRA/chemotherapy arms, respectively. Significant results were observed in terms of EFS, cumulative incidence of relapse, and OS at 50 months in the ATRA/ATO arm \[97% vs 80%, *P* = 0.001; 1.9% vs 13.9%, *P* = 0.001; 99% vs 93%, *P* = 0.007, respectively\], while induction death occurred only in the ATRA/chemotherapy arm (3%). The British group enrolled 235 patients in a randomized study of newly diagnosed patients comparing ATRA plus idarubicin as induction followed by ATRA/chemotherapy consolidation versus ATRA/ATO \[[@CR7]\]. Ninety-three percent of the 30 high-risk patients and 7 low-risk patients who received the ATRA/ATO arm also received GO for their high WBC count. The CR rate was 94% in the ATRA/ATO arm vs 89% in the ATRA/chemotherapy arm. The 4-year EFS was significantly better in the ATRA/ATO arm (91% vs 70%; *P* = 0.002). This significant benefit was apparent in the low-risk group but not in the high-risk group. It therefore appears that ATRA/ATO alone was not enough for the high-risk group, so the optimal therapy for high-risk patients remains unclear. Iland et al. showed that ATRA/ATO plus chemotherapy is superior to ATRA plus chemotherapy in all-risk APL patients \[[@CR9], [@CR217]\]. Burnett et al. found that ATRA/ATO treatment is feasible for high-risk patients who receive GO for their high WBC count \[[@CR7]\]. In the APL4 trial from the Australia--New Zealand group, idarubicin was incorporated into the ATRA/ATO induction regimen, followed by ATRA/ATO consolidation therapy \[[@CR127]\]. This is also the case in the current multinational phase III APOLLO trial that randomizes ATRA/ATO plus idarubicin versus the AIDA regimen in newly diagnosed high-risk APL patients. In arm A, induction with ATRA is supplemented by two administrations of idarubicin on days 1 and 3, respectively, and ATO starting on day 5 after the start of idarubicin. The induction therapy is followed by 4 courses of ATO/ATRA-based consolidation. In arm B, standard AIDA-based induction comprises idarubicin on days 1, 3, 5, and 7 combined with daily ATRA therapy until CR is achieved. Upon achieving hematological CR, patients start three cycles of consolidation including ATRA combined with Ara-C, idarubicin, and mitoxantrone, followed by 2 years of maintenance therapy. Patients with leukocytosis may have a high risk of CNS relapse \[[@CR111]\]. The first prevention measure is to decrease the WBC count using hydroxyurea or chemotherapy. The second could be to increase the blood--brain barrier permeability of ATO by mannitol infusion \[[@CR218], [@CR219]\]. While maintenance therapy was originally part of the design of the ATRA/chemotherapy regimen, the role of maintenance has come into question in the era of ATRA/ATO therapy. In the low/intermediate-risk group, maintenance therapy can be safely omitted after the ATRA/ATO regimen. In the high-risk group, it could also be omitted if the ATRA/ATO regimen is used in conjunction with a cytotoxic agent such as idarubicin, and if molecular remission has been achieved at the end of consolidation. Recently, prolonged therapy with ATRA and ATO was tested in the relapse setting and the results confirmed the potentially curative effect of this regimen in relapsed APL, especially in patients with a long first CR \[[@CR220]\].Table 5Published studies of the use of the ATRA/ATO combination in frontline therapyReferencePatientsCREFSOSEstey et al. \[[@CR207]\]LR: 25HR: 19LR: 96%HR: 79%NDNDRavandi et al. \[[@CR208]\]LR: 56HR: 26LR: 95%HR: 81%LR: 89% (3y)HR: 65% (3y)LR: 89% (3y)HR: 75% (3y)Hu et al. \[[@CR205]\]8594%89% (5y)92% (5y)Lo-Coco et al. \[[@CR8]\]ATRA/ATO: 77ATRA/CT: 79ATRA/ATO: 100%ATRA/CT: 86%ATRA/ATO: 97% (2y)ATRA/CT: 86% (2y)ATRA/ATO: 99% (2y)ATRA/CT: 91% (2y)Burnett et al. \[[@CR7]\]ATRA/ATO: 116ATRA/CT: 119ATRA/ATO: 94%ATRA/CT: 89%ATRA/ATO: 91% (4y)ATRA/CT: 70% (4y)ATRA/ATO: 93% (4y)ATRA/CT: 89% (4y)Abaza et al. \[[@CR215]\]LR: 133HR: 54LR: 96%HR: 96%LR: 87% (5y)HR: 81% (5y)LR: 89% (5y)HR: 86% (5y)Platzbecker et al. \[[@CR216]\]ATRA/ATO: 127ATRA/CT: 136ATRA/ATO: 100%ATRA/CT: 97%ATRA/ATO: 97% (4y)ATRA/CT: 80% (4y)ATRA/ATO: 99% (4y)ATRA/CT: 93% (4y)*ATO* arsenic trioxide, ATRA, all-*trans* retinoic acid, *CR* complete remission, *CT* chemotherapy, *EFS* event-free survival, *HR* high-risk, *LR* low-risk, *ND* not done, *OS* overall survival, *y* years

### Mechanisms of the Synergistic Effect of ATRA-ATO {#Sec21}

Distinct APL mouse models highlighted a synergy between ATRA and ATO \[[@CR212], [@CR221]\]. This combination enhanced apoptosis but not differentiation and accelerated APL clearance. The two drugs exert synergistic effects in regard to the loss of self-renewal, most likely through cooperative PML-RARA degradation. PML/RARA disrupts PML nuclear bodies and deregulates transcriptional control through the recruitment of corepressor complexes. PML/RARA ultimately induces enhanced self-renewal and a differentiation block \[[@CR200], [@CR222]\]. Nuclear bodies are stress-sensitive nuclear domains involved in p53 activation and the control of senescence \[[@CR223], [@CR224]\]. Other functions have been attributed to PML/RARA, which is also influenced by important genetic modulators \[[@CR225]--[@CR229]\]. ATRA and ATO bind to the PML-RARA fusion oncoprotein and initiate proteolytic degradation of PML-RARA \[[@CR222]\]. The binding of ATRA to RARA activates PML/RARA target gene transcription and initiates fusion protein degradation. The binding of ATO to the PML part triggers PML/RARA conjugation by SUMO, resulting in its degradation \[[@CR230]\]. The key role of oncoprotein catabolism in leukemia eradication was shown by exploring the response to ATRA or ATO in mice. Degradation of PML-RARA reverses transcriptional repression and triggers a PML/p53-dependent senescence checkpoint. In mouse models, arsenic was shown to act on both the PML-RARA oncoprotein and the remaining normal PML protein, which drives p53 activation and senescence \[[@CR196]\]. PML-RAR degradation is required to stop APL cell self-renewal, and it predicts long-term APL clearance. A contribution of the immune system to the response to therapy has also been suggested because of the diminished antileukemic activity observed in immune-compromised mice \[[@CR231]\]. The immune system seems to be important for eliminating senescent cells involved in APL clearance \[[@CR232], [@CR233]\]. Partner-mediated RARA dimerization is believed to be essential for arresting differentiation \[[@CR234], [@CR235]\], and transformation requires the PML coiled-coil domain \[[@CR236]\]. Mutations at the arsenic-binding site of PML explain therapy resistance and why arsenic only cures 70% of APL patients when used as a single agent \[[@CR199]\]. Similarly, ATRA acts on not only PML-RARA but also the Pin-1 enzyme, the overexpression of which favors transformation in multiple cell types, or PHF8-mediated transcriptional activation \[[@CR225], [@CR237]\].

APL is a hematological malignancy driven by the PML-RARA oncogene. ATRA and ATO were both shown to target PML-RARA, explaining their strong specificity for APL. Standard-risk APL can now be cured in virtually all patients with a combination of ATRA and ATO.

Conclusions and Perspectives {#Sec22}
============================

Constant progress in the treatment of APL has caused the status of APL to evolve from highly fatal to highly curable. The current results show high CR rates and high 5-year DFS rates. The superiority of ATRA-ATO compared to the conventional ATRA-chemotherapy regimen is indisputable in the low- and intermediate-risk groups, which no longer require chemotherapy, but not in the high-risk group. Results obtained in the Italian-German APL0406 trial \[[@CR8]\] led the NCCN and a Canadian expert panel to indicate this regimen as a new standard of care in this setting \[[@CR113], [@CR238]\]. However, there are still open issues in this area, notably regarding the type of ATO schedule. Regimens for high-risk APL have not been compared sufficiently to be able to draw final conclusions. Preliminary evidence from trials combining ATRA-ATO with chemotherapy indicate a high efficacy of ATO in this subset of patients and suggest that this triple combination may be curative in high-risk patients \[[@CR7], [@CR9]\]. However, the type and dose of initial chemotherapy needed during induction in combination with ATRA-ATO remain to be determined. ATRA-ATO therapy may also serve as an attractive alternative for patients who are considered unfit for conventional therapy. The impressive improvement in APL outcomes has recently been challenged by registry-based studies exploring APL outcomes in the real world \[[@CR239]--[@CR241]\]. These studies indicate that early mortality is currently an underestimated phenomenon in clinical trials. There is an ongoing need to decrease the early death rate (within the first 30 days from diagnosis), which is still the primary cause of treatment failure rather than the resistant disease that is so common for all other subtypes of AML \[[@CR242]\]. Large clinical trials have reported an early death rate of 3--10% \[[@CR8], [@CR130], [@CR217]\]. However, the death rate has been reported to be approximately 20% in patients who were ineligible or excluded from trials \[[@CR243]\]. In large population-based analyses, and among patients treated in single institutions, the rate of mortality is even higher and can range from 9.6% to 61.5% \[[@CR244]\]. An explanation for this high rate of early death is the rarity of APL coupled with the fact that the majority of APL patients in some countries are treated outside clinical trials and in smaller inexperienced centers. Some studies have identified prognostic factors that are capable of predicting early deaths. In multicenter studies, the most frequent causes of death were identified as bleeding, differentiation syndrome, infection, and multiorgan failure. Cerebral hemorrhage and severe infection are generally involved in early deaths, which primarily occur in patients with hyperleukocytosis \[[@CR245]\]. Delays in ATRA therapy have been suggested as a contributing factor to early deaths \[[@CR246]\], as has initial hospitalization in nonspecialized primary care institutions \[[@CR241], [@CR247]\]. A risk classification system was recently proposed to identify the subgroup at a high risk of early death among APL patients in not only de novo but also relapse cohorts \[[@CR248]\]. Overall, the rapid identification and treatment of newly diagnosed APL patients, particularly older patients, remain challenging. This emphasizes the need for rapid supportive care together with immediate access to ATRA-based therapy \[[@CR249]\]. Better-trained hematologists and better health insurance coverage in developing countries could further reduce early deaths \[[@CR250]\]. Other current concerns involve APL treatment in children, post-ATO relapses, refinements to strategies for high-risk APL, and the introduction of a new drug formula with an attempt to give only oral ambulatory therapy. Despite the dramatic improvement achieved in frontline therapy of childhood APL with the combination of ATRA and anthracycline-based regimens, relapse and chemotherapy-associated side effects still represent non-negligible causes of treatment failure and morbidity \[[@CR251]\]. A frontline treatment approach based on the ATRA-ATO combination has been explored in a limited number of pediatric patients \[[@CR252]--[@CR254]\]. All patients achieved molecular CR after a median time of 10 weeks but experienced hyperleukocytosis, which could require the administration of chemotherapy or hydroxycarbamine \[[@CR253], [@CR254]\]. A prospective multicenter European trial from the International Consortium for Childhood APL is ongoing. Current literature on the treatment of relapsed APL focuses on the period after ATRA and chemotherapy. It is likely that the current scenario of APL relapse will change, and the clinical and biological features of post-ATO relapses as well as their optimal management should be examined in future investigations. The addition of a few days of idarubicin or new therapeutic agents to the ATRA-ATO regimen has been suggested for the high-risk group. GO is an anti-CD33 (a differentiation antigen detectable in almost 100% of APL patients) antibody calicheamicin conjugate that can yield a high molecular remission rate when used as a single agent in APL \[[@CR255]\]. The combination of GO with ATRA-ATO therapy was tested by the MD Anderson Cancer Center \[[@CR208]\]. SNG-CD33A, a next-generation anti-CD33 antibody, has demonstrated antileukemic activity in a phase 1 study \[[@CR256]\]. Another anti-CD33, HuM195, has demonstrated efficacy on MRD \[[@CR257]\]. Because of mutations detected in 25--45% of cases, *FLT3* inhibitors could find application in the treatment of APL.*FLT3* inhibitor SU11657 in combination with ATRA induced rapid regression of leukemia in an animal model \[[@CR258]\]. Tamibarotene (formerly called Am80), a synthetic retinoic acid with more potent in vitro activity than ATRA, has demonstrated a favorable pharmacokinetic profile, as the plasma level does not decline after daily administration \[[@CR259]\]. It produced interesting results when used as a single agent for induction in relapsed/refractory patients who previously received ATRA and ATO \[[@CR260]\]. In a study reported by the Japan Adult Leukaemia Study Group, tamibarotene led to an improvement in relapse-free survival (RFS) when used as a maintenance therapy in high-risk APL \[[@CR110]\]. When applied as a maintenance therapy, tamibarotene was significantly superior to ATRA in terms of decreasing relapse in high-risk patients \[[@CR261]\]. Another arsenic compound named the Realgar-Indigo naturalis formula, a traditional Chinese oral medicine containing As~4~S~4~, has been shown to be highly effective when used to treat APL. This represents a more convenient route of administration than the standard intravenous regimen. Oral arsenic has shown favorable oral absorption, leading to a bioavailability of up to 95% of an equivalent dose of intravenous ATO \[[@CR262]\]. It was first tested in relapsed APL cases, where it showed high efficacy and no QTc prolongation and ventricular arythmias, in contrast with intravenous ATO, likely because its peak plasma concentrations were lower \[[@CR263]\]. The use of oral arsenic (tetra-arsenic tetra-sulfide As~4~S~4~) in combination with ATRA has shown efficacy for high-risk APL \[[@CR264]\] and a noninferior outcome in non-high-risk APL when compared with intravenous ATO plus ATRA in trials including adults and children \[[@CR265]--[@CR267]\]. The rates of adverse events were similar \[[@CR268]\], and the oral combination As~4~S~4~-ATRA has demonstrated the feasibility of out-of-hospital treatment and reducing hospital stay \[[@CR267], [@CR269]\]. Oral ATO was also tested in the setting of maintenance therapy after first CR, and produced similar results to the intravenous formulation \[[@CR270]\]. However, the relative contribution of maintenance therapy remains controversial. A recent Cochrane meta-analysis could not show a benefit of maintenance for OS, despite an improvement in DFS \[[@CR271]\]. Recent trials incorporating ATO have demonstrated that success can be achieved without any maintenance in non-high-risk patients \[[@CR7], [@CR8], [@CR272]\].

APL is the best example of how targeted therapies can trigger definitive cures. ATRA-ATO combination therapy illustrates the importance of traditional medicine and represents the first model of molecular target based therapy. Several expert panels have recommended that molecular remission should be considered a therapeutic objective in APL, and molecular response has been adopted as a study endpoint in modern clinical trials \[[@CR273]\]. APL patients around the world should soon undergo this curative treatment, perhaps based on oral formulations \[[@CR274]\]. Oral administration raises the possibility of implementing treatment as outpatient care, thus increasing quality of life and decreasing medical costs \[[@CR269], [@CR275]\]. Along with the introduction of tyrosine kinase inhibitor therapy in chronic myeloid leukemia, the ATRA-ATO combination represents one of the most important advances in hematological disease therapy over the last three decades, and provides a model for the way in which cancer should be treated.
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